MicroRNA-29c Functions as a Tumor Suppressor by Targeting VEGFA in Lung Adenocarcinoma

Liu, L.; Bi, Nan; Wu, Leilei; Ding, Xi; Men, Yu; Wang, Zhou; Li, L.; Zhang, W.; Shi, Si; Song, Yong; Wang, L.

doi:10.1016/j.ijrobp.2017.06.2057

Cited by 9 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-29c, which inhibits cell proliferation, promotes apoptosis and arrests cell cycle at G1/G0 phase by targeting the Nuclear autoantigenic sperm protein, is downregulated in gastric cancer tissues and cell lines (20). miR-29c inhibits proliferation, migration and invasion in lung cancer cell lines by targeting vascular endothelial growth factor A in vitro (35). The present study provides evidence that miR-29c downregulates SIRT1 by targeting the 3'-UTR of SIRT1 mRNA.…”

Section: Discussionsupporting

confidence: 50%

MicroRNA‑29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression

Zhang

Luo

2018

Oncol Lett

View full text Add to dashboard Cite

Liver cancer is one of the most prevalent human tumors in the world. Despite recent advances regarding the understanding of the molecular basis of liver cancer and the introduction of novel chemotherapeutic approaches, liver cancer remains associated with a poor prognosis. Sirtuin 1 (SIRT1) was identified to be abnormally upregulated in liver cancer. Dysregulation of microRNAs (miRs/miRNAs) is associated with a variety of types of cancer, and miRNAs may also serve a role in tumorigenesis and progression. The present study demonstrated that following the selection of the cisplatin chemoresistant HepG2 cell line, miR-29c is downregulated using reverse transcription-quantitative polymerase chain reaction. Furthermore, overexpression of miR-29c in cisplatin-resistant cancer cells was demonstrated to inhibit tumor cell proliferation and to promote apoptosis and, as well as restoring cisplatin chemosensitivity by using a cell counting assay, colony formation assay, Annexin V-fluorescein isothocyanate/propidium iodide apoptosis analysis, terminal deoxynucleotidyl transferase dUTP nick end labeling and xenograft tumors in nude mice. Mechanistically, according to bioinformatics analysis and a luciferase assay, miR-29c may directly target SIRT1 mRNA and repress SIRT1 expression, which is positively associated with the chemoresistance of liver cancer and may ultimately provide a novel therapeutic method.

show abstract

Section: Discussionsupporting

confidence: 50%

MicroRNA‑29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression

Zhang

Luo

2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Meanwhile, VEGFA was also found to be markedly upregulated in other tumours. The overexpression of VEGFA is a powerful predictor of overall survival and progression for some cancers, including breast cancer, prostate cancer, lung cancer and glioma [20][21][22][23][24]. Additionally, VEGFA was also demonstrated to increase the motility of PDAC cells [25].…”

Section: Introductionmentioning

confidence: 99%

Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa‐miR‐29b‐3p in pancreatic ductal adenocarcinoma

Zhao

Liu

et al. 2017

J Cellular Molecular Medi

124

126

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Long non‐coding RNAs (lncRNAs) are important regulators in pathological processes, yet their potential roles in PDAC are poorly understood. Here, we identify a fundamental role for a novel lincRNA, linc00511, in the progression of PDAC. Linc00511 levels in PDAC tissue specimens and cell lines were examined by quantitative real‐time PCR. Corresponding adjacent non‐neoplastic tissues were used as controls. The function of linc00511 in PDAC cell lines was determined by RNA interference approach in vitro and in vivo. Fluorescence in situ hybridization (FISH) was used to characterize linc00511 expression in PDAC cells. Insights of the mechanism of competitive endogenous RNAs (ceRNAs) were obtained from bioinformatic analysis, luciferase assays and RIP assays. The association between the linc00511/hsa‐miR29b‐3p axis and VEGFA was verified by Western blotting assay. Immunohistochemistry was performed to evaluate the expression of VEGFA in PDAC samples. The aberrant up‐regulation of linc00511 was detected in PDAC cell lines and patient specimens compared with controls. An increase in linc00511 expression indicates the adverse clinical pathological characteristics and poor prognosis. Functionally, linc00511 depletion in PDAC cells decreased proliferation, migration, invasion and endothelial tube formation. Mechanistically, linc00511 could up‐regulate VEGFA via its competing endogenous RNA (ceRNA) activity on hsa‐miR‐29b‐3p. In summary, our results define an important axis controlling proliferation, invasion and tumour angiogenesis in PDAC. Linc00511 is a novel lncRNA that plays a significant regulatory role in the pathogenesis and progression of PDAC. Thus, Linc00511 represents a new prognostic biomarker to predict clinical outcome of PDAC patients after surgery and may serve as a potential therapeutic target for PDAC treatment.

show abstract

“…NSCLC is a multifactorial malignancy with several risk factors, such as a history of smoking, exposure to asbestos and malnutrition, which all can increase the incidence of NSCLC [3]. Although various treatments are available for patients with NSCLC, such as surgery, chemotherapy and angiogenesis, and lymphangiogenesis of NSCLC by targeting several angiogenic factors, including VEGF and LATS2 [7][8][9][10][11][12][13][14][15]. However, few clinical studies have investigated the correlation between circulating miRNAs related to angiogenesis and the prognosis of NSCLC.…”

Section: Introductionmentioning

confidence: 99%

High circulating miR‐18a, miR‐20a, and miR‐92a expression correlates with poor prognosis in patients with non‐small cell lung cancer

Zhu

Zeng

et al. 2017

Cancer Medicine

View full text Add to dashboard Cite

The purpose of this study was to assess the predictive value of angiogenic miRNAs for disease‐free survival (DFS) and overall survival (OS) of patients with non‐small cell lung cancer (NSCLC). In total, 196 patients with NSCLC (tumor lymph nodes metastasis (TNM) stage I–III) were enrolled and peripheral blood samples were collected. Total RNA was extracted from blood samples, and the relative expression levels of candidate miRNAs were evaluated by real time‐polymerase chain reaction (RT‐PCR). The median follow‐up period was 56.7 months, and the final follow‐up date was in August 2016. The median DFS of all patients was 30.0 (14.0–49.0) months, whereas the median OS was 41.5 (23.0–58.0) months. Furthermore, the 5‐year DFS and OS rates were 11.3% and 32.3%, respectively. Kaplan–Meier (K–M) curves showed that high plasma miR‐18a (P < 0.001), miR‐20a (P < 0.001), miR‐92a (P < 0.001), miR‐126 (P < 0.001), miR‐210 (P = 0.003), and miR‐19a (P = 0.027) expressions levels correlated with a worse DFS. Moreover, patients with high plasma miR‐18a, miR‐20a, miR‐92a, miR‐210, and miR‐126 expression levels had a shorter OS than patients with low expression levels of these miRNAs (all P <= 0.001). Furthermore, multivariate Cox regression analyses revealed that high plasma expression levels of miR‐18a, miR‐20a, and miR‐92a as well as lymphatic node metastasis (all P < 0.001) were independent risk factors for both DFS and OS in patients with NSCLC. Thus, the circulating miR‐18a, miR‐20a, and miR‐92a levels may serve as novel and promising prognostic biomarkers in patients with NSCLC.

show abstract

MicroRNA-29c Functions as a Tumor Suppressor by Targeting VEGFA in Lung Adenocarcinoma

Cited by 9 publications

References 24 publications

MicroRNA‑29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression

MicroRNA‑29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression

Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa‐miR‐29b‐3p in pancreatic ductal adenocarcinoma

High circulating miR‐18a, miR‐20a, and miR‐92a expression correlates with poor prognosis in patients with non‐small cell lung cancer

Contact Info

Product

Resources

About